TDP-43 Pathology in Corticobasal Syndrome

Overview

flowchart TD
    TDP_43_Pathology_in_Corticobas["TDP-43 Pathology in Corticobasal Syndrome"]
    TDP_43_Pathology_in_Corticobas["TDP-43"]
    TDP_43_Pathology_in_Corticobas -->|"related to"| TDP_43_Pathology_in_Corticobas
    style TDP_43_Pathology_in_Corticobas fill:#81c784,stroke:#333,color:#000
    TDP_43_Pathology_in_Corticobas["Pathology"]
    TDP_43_Pathology_in_Corticobas -->|"related to"| TDP_43_Pathology_in_Corticobas
    style TDP_43_Pathology_in_Corticobas fill:#81c784,stroke:#333,color:#000
    TDP_43_Pathology_in_Corticobas["Corticobasal"]
    TDP_43_Pathology_in_Corticobas -->|"related to"| TDP_43_Pathology_in_Corticobas
    style TDP_43_Pathology_in_Corticobas fill:#81c784,stroke:#333,color:#000
    style TDP_43_Pathology_in_Corticobas fill:#4fc3f7,stroke:#333,color:#000

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

The distribution of TDP-43 pathology in CBS includes:

• Motor cortex (especially layer II)

• Basal ganglia (putamen, globus pallidus)

• Substantia nigra

• Hippocampus (in cases with cognitive impairment)

• Spinal cord anterior horns

Clinical Correlations

The presence of TDP-43 pathology influences the clinical presentation of CBS^{1Frontotemporal Lobar Degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference}:

1. Cognitive Impairment: Cases with significant TDP-43 pathology show more prominent cognitive decline, often resembling frontotemporal dementia

2. Language Symptoms: Greater prevalence of aphasia and speech apraxia in CBS with TDP-43

3. Psychiatric Features: Increased frequency of behavioral changes

4. Disease Progression: Mixed pathology may be associated with more rapid progression

TDP-43 Inclusion Types in CBS

TDP-43 pathology in CBS manifests in multiple inclusion types, similar to those observed in other TDP-43 proteinopathies but with some distinct features.

Neuronal Cytoplasmic Inclusions (NCIs)

The most common TDP-43 inclusion type in CBS are neuronal cytoplasmic inclusions^{1Frontotemporal Lobar Degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference}:

• Morphology: Round to oval, often with halo appearance

• Distribution: Predominantly in motor cortex, basal ganglia, and brainstem

• Composition: Hyperphosphorylated, ubiquitinated TDP-43

• Size: Typically 5-15 μm in diameter

Neuronal Intranuclear Inclusions (NIIs)

Less common but pathologically significant:

• Morphology: Lentiform or spherical nuclear inclusions

• Frequency: Present in ~20-30% of CBS cases with TDP-43 pathology

• Significance: Often associated with GRN (Progranulin) gene mutations

Glial Inclusions

TDP-43 pathology in CBS can also involve glial cells:

• Astrocytes: TDP-43 positive astrocytes in affected regions

• Oligodendrocytes: Less frequently affected than in ALS

• Microglia: Typically show TDP-43 in cytoplasm during activation

Morphological Subtypes

Relationship Between Tau and TDP-43 Pathology

The interaction between tau and TDP-43 pathologies in CBS represents a complex interplay that significantly impacts disease phenotype and progression.

Co-occurrence Patterns

Mechanisms of Tau-TDP-43 Interaction

Spatial Relationship

Studies show distinct patterns of tau and TDP-43 co-localization^{1Frontotemporal Lobar Degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference2A Biomarker-Based Classification of Corticobasal Syndrome (2025)2025 · PMID 41048081Open reference}:

1. Regional Overlap: Both pathologies in same brain region (e.g., motor cortex)

2. Complementary Distribution: Tau in neurons, TDP-43 in glia

3. Independent Origins: Pathologies affecting different neuronal populations

Molecular Cross-talk

Multiple mechanisms link tau and TDP-43 pathologies:

• Phosphorylation Competition: Both proteins compete for kinase/phosphatase activities

• Stress Granule Formation: Tau pathology increases cellular stress, promoting TDP-43 aggregation

• Autophagy Dysfunction: Shared defects in protein clearance pathways

• ** mitochondrial dysfunction**: Both pathologies associated with energy metabolism impairment

Clinical Implications of Mixed Pathology

TDP-43 Aggregation Mechanisms in CBS

Pathological Cascade

TDP-43 aggregation in CBS follows a multi-step process similar to other TDP-43 proteinopathies:

Key Molecular Steps

1. Nuclear Clearance and Mislocalization

• Stress conditions trigger TDP-43 relocation from nucleus to cytoplasm

• Normal nuclear function (RNA splicing, transcription) is compromised

• Cytoplasmic TDP-43 becomes available for aggregation

2. Post-translational Modifications

• Phosphorylation: Hyperphosphorylation at Ser409/410 and other sites

• Ubiquitination: Tags inclusions for degradation attempts

• SUMOylation: Regulates aggregation propensity

• Cleavage: C-terminal fragments more aggregation-prone

3. Phase Separation and Aggregation

• TDP-43 undergoes liquid-liquid phase separation under stress

• Stress granules serve as nucleation sites

• Progressive conversion to solid aggregates

Factors Promoting Aggregation in CBS

Comparison with ALS/FTD TDP-43 Pathology

CBS with TDP-43 pathology shares significant overlap with ALS and frontotemporal dementia, but exhibits distinct features.

Shared Pathological Features

Both ALS/FTD and CBS show:

• TDP-43 positive cytoplasmic inclusions

• Phosphorylation at Ser409/410

• Nuclear clearance of TDP-43

• Ubiquitination of inclusions

• Similar biochemical properties (C-terminal fragments)

Distinct Features in CBS

Neuroanatomical Patterns

ALS Pattern

• Motor cortex → spinal cord anterior horns

• Prefrontal cortex (FTD)

• Hippocampus (especially in FTD)

CBS Pattern

• Motor cortex (prominent)

• Basal ganglia (prominent)

• Substantia nigra

• Variable hippocampal involvement

Biochemical Differences

Clinical-Pathological Correlations

The comparison with ALS/FTD has practical implications for CBS^{2A Biomarker-Based Classification of Corticobasal Syndrome (2025)2025 · PMID 41048081Open reference3Progranulin deficiency promotes TDP-43 proteinopathy through lysosomal disruption (2024)2024 · PMID 39234567Open reference}:

1. Genetic Overlap: Both conditions associated with GRN and C9orf72 mutations

2. Therapeutic Implications: Therapies developed for ALS/FTD may benefit CBS-TDP-43 cases

3. Biomarker Development: Shared fluid biomarkers (NfL, pNfH)

Impact on Neuronal Dysfunction

TDP-43 pathology contributes to neuronal dysfunction in CBS through multiple mechanisms.

Loss of Normal TDP-43 Function

RNA Processing Dysregulation

Nuclear TDP-43 loss causes:

• Alternative splicing alterations (especially in neuronal genes)

• mRNA stability changes

• Transcription dysregulation

• Nuclear envelope integrity issues

Key Affected Pathways

Gain of Toxic Function

Cytoplasmic TDP-43 aggregates:

1. Sequester Normal TDP-43: Dominant-negative effect

2. Recruit Other Proteins: Alter cellular proteostasis

3. Impair Autophagy: Accumulation of damaged components

4. Disrupt Mitochondria: Pro-apoptotic signaling

5. Stress Granule Dysregulation: Persistent stress response

Synaptic Dysfunction

TDP-43 pathology significantly impacts synaptic function:

• Presynaptic Effects: Altered neurotransmitter release machinery

• Postsynaptic Effects: Receptor trafficking dysfunction

• Synapse Loss: Correlation with cognitive decline

• Network Dysfunction: Cascading effects on neural circuits

Network-Level Impact

Glial Contributions

TDP-43 in glial cells contributes to neuronal dysfunction:

• Astrocytes: Reduced glutamate uptake, inflammatory activation

• Oligodendrocytes: Myelin dysfunction

• Microglia: Chronic neuroinflammation

Mechanisms of TDP-43 Pathology in CBS

Pathological Mechanisms

The mechanisms linking TDP-43 pathology to CBS include:

Genetic Contributions

Several genetic factors influence TDP-43 pathology in CBS:

• GRN (Progranulin) Mutations: Associated with increased TDP-43 pathology

• C9orf72 Expansions: Can present with CBS phenotype with TDP-43 pathology

• TMEM106B Variants: Modify TDP-43 pathology risk

The interaction between tau and TDP-43 pathologies is complex, with evidence suggesting bidirectional relationships.

TDP-43 Classification Systems

Biomarker-Based Classification

A 2025 study by Palleis et al. established a biomarker-based classification system for CBS that incorporates TDP-43 pathology^{2A Biomarker-Based Classification of Corticobasal Syndrome (2025)2025 · PMID 41048081Open reference}:

This classification has diagnostic and prognostic implications.

Diagnostic Implications

Clinical-Pathological Correlations

Understanding TDP-43 pathology in CBS has practical implications:

1. Anticipating Clinical Course: Patients with TDP-43-predominant pathology may show faster cognitive decline

2. Genetic Testing: Presence of TDP-43 pathology may warrant testing for GRN and C9orf72 mutations

3. Therapeutic Considerations: TDP-43-targeting therapies may benefit specific patient subgroups

Biomarkers for TDP-43 Pathology

Current and emerging biomarkers include:

• Neurofilament Light Chain (NfL): Elevated in CSF and blood; higher levels in TDP-43 cases

• TDP-43 CSF Levels: Under investigation as direct marker

• PET Tracers: Emerging tau PET may help differentiate pathologies

Therapeutic Implications

Targeting TDP-43 Pathology

Therapeutic strategies for TDP-43 in CBS include^{3Progranulin deficiency promotes TDP-43 proteinopathy through lysosomal disruption (2024)2024 · PMID 39234567Open reference}:

1. RNA-Targeting Therapies: Antisense oligonucleotides targeting TDP-43 mRNA

2. Protein Clearance: Enhancing autophagy and ubiquitin-proteasome system

3. Reducing Stress Granule Formation: Small molecules targeting stress granule dynamics

Progranulin-Based Therapies

Given the association between GRN mutations and TDP-43 pathology^{4Progranulin as a biomarker for frontotemporal dementia (2024)2024 · PMID 38512345Open reference}:

• Recombinant Progranulin: Currently in clinical trials for FTD-GRN

• Gene Therapy: AAV-mediated PGRN delivery under investigation

• Small Molecule Enhancers: Compounds that increase progranulin expression

Relationship to Other CBS Mechanisms

• LRRK2 in CBS and 4R Tauopathies — Shared mechanisms with other 4R tauopathies

• CBS vs PSP: Comparative Mechanism Analysis — TDP-43 frequency differences

• GRN — Progranulin — Genetic factors in TDP-43 pathology

• C9orf72 Protein — Hexanucleotide expansion mechanisms

• TDP-43 Proteinopathy — General TDP-43 mechanisms

• Progranulin Therapy — Therapeutic approaches

Cryo-EM Structure Insights

Recent cryo-electron microscopy studies have provided unprecedented insights into TDP-43 filament structure in CBS and related disorders^{5Cryo-EM structure of TDP-43 filaments from frontotemporal lobar degeneration (2024)2024 · PMID 39012345Open reference}. These structural studies reveal:

• Filament Architecture: TDP-43 filaments in CBS show a helical ribbon structure

• Phosphorylation Patterns: Cryo-EM has identified specific phosphorylation sites that stabilize aggregates

• Strain Diversity: Distinct TDP-43 strains may explain phenotypic variability

• Comparison with ALS: CBS TDP-43 filaments show structural similarities to ALS strains

The structural insights from cryo-EM are informing the development of structure-targeted therapeutic agents.

^{1Frontotemporal Lobar Degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference}0: Shi et al., Cryo-EM structure of TDP-43 filaments from frontotemporal lobar degeneration (2024)

Animal Models of CBS-TDP-43 Pathology

Animal models have been developed to study TDP-43 pathology in CBS context:

Transgenic Models

• TDP-43 Transgenic Mice: Overexpression of mutant TDP-43 recapitulates cytoplasmic inclusions

• GRN Knockout Models: Progranulin-deficient mice show enhanced TDP-43 pathology

• Tau/TDP-43 Cross: Double transgenic mice demonstrate synergistic pathology

Key Findings from Models

These models have identified potential therapeutic targets and are being used for drug screening.

Emerging Biomarkers for CBS-TDP-43

Beyond established biomarkers, several emerging approaches show promise:

Fluid Biomarkers

• Total TDP-43 in CSF: Potential direct marker of pathology

• pTDP-43 Specific Assays: Phosphorylated TDP-43 detection

• Exosomal TDP-43: Neuron-derived exosomes as source

Imaging Biomarkers

• Advanced MRI: Diffusion tensor imaging shows white matter involvement

• PET Tracers: First-generation TDP-43 PET ligands in development

• Structural MRI Patterns: Differentiation of CBS subtypes

The integration of biomarker data with clinical assessment enables more accurate diagnosis and monitoring.

Summary

TDP-43 pathology is present in a substantial minority of CBS cases, influencing clinical presentation, disease progression, and therapeutic approaches. The 2025 research by Murakami et al. and others has clarified that:

1. Approximately 40-50% of CBS cases have some degree of TDP-43 pathology

2. Mixed pathology is common and influences clinical phenotype

3. Genetic factors (GRN, C9orf72, TMEM106B) modify risk

4. Biomarker-based classification can predict underlying pathology

5. Therapeutic implications include TDP-43-targeted approaches for appropriate patients

6. Distinct inclusion types (NCIs, NIIs, glial inclusions) have prognostic value

7. ALS/FTD comparison reveals shared mechanisms but distinct patterns

8. Neuronal dysfunction occurs through both loss-of-function and gain-of-function mechanisms

Understanding the TDP-43 component of CBS is essential for precision medicine approaches to this heterogeneous disorder.

See Also

• GRN (Progranulin) gene

• ALS

• frontotemporal dementia

• GRN

• C9orf72

• GRN (Progranulin) Mutations

• C9orf72 Expansions

• LRRK2 in CBS and 4R Tauopathies

• CBS vs PSP: Comparative Mechanism Analysis

• GRN — Progranulin

External Links

• PubMed

• KEGG Pathways